# A Study of ATG-201 in Adult Participants With Autoimmune Diseases

> **NCT07732309** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Antengene Biologics Limited** · enrollment: 149 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus
- Systemic Sclerosis (SSc)
- Sjogren's Disease
- Autoimmune Diseases

## Interventions

- **DRUG:** ATG-201

## Key facts

- **NCT ID:** NCT07732309
- **Lead sponsor:** Antengene Biologics Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2028-12-01
- **Final completion:** 2029-06-01
- **Target enrollment:** 149 (ESTIMATED)
- **Last updated:** 2026-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07732309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07732309, "A Study of ATG-201 in Adult Participants With Autoimmune Diseases". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07732309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*